Avalo Therapeutics, Inc.
18.04-0.34 (-1.85%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · AVTX · USD
Key Stats
Market Cap
321.11MP/E (TTM)
2.76Basic EPS (TTM)
6.54Dividend Yield
0%Recent Filings
8-K
8-K
AVTX-009 HS trial update
Avalo Therapeutics updated its investor presentation on October 10, 2025, spotlighting AVTX-009, a high-affinity IL-1β inhibitor targeting hidradenitis suppurativa's unmet needs amid incomplete responses to anti-TNF and anti-IL-17 therapies. The Phase 2 LOTUS trial is enrolling biologic-naïve and experienced patients, with topline data due mid-2026; HS market growth to over $10B by 2035 underscores potential. Cash of $112 million extends runway into 2028. Forward-looking statements carry risks from trials and markets.
8-K
Boyd joins as CBO
Avalo Therapeutics appointed Taylor Boyd as Chief Business Officer on October 1, 2025, to bolster its business development amid advancing AVTX-009 through Phase 2 trials for hidradenitis suppurativa. Boyd, with 15 years in biotech deals including Longboard's $2.6 billion sale, receives a $465,000 base salary, 40% target bonus, and options for 275,000 shares vesting over four years. This hire sharpens Avalo's edge in partnerships. Yet risks linger in clinical timelines.
8-K
Q2 loss amid trial progress
Avalo Therapeutics reported a Q2 2025 net loss of $20.8 million, up from net income of $98.5 million last year due to a one-time warrant gain and rising R&D costs for the Phase 2 LOTUS trial. The trial, testing AVTX-009 in hidradenitis suppurativa, has enrolled over three-quarters of 222 patients and expects topline data mid-2026. Cash stands at $113.3 million, funding operations into 2028. Rita Jain, M.D., joined the board, adding clinical expertise. Strong cash position supports trial momentum.
10-Q
Q2 FY2025 results
Avalo Therapeutics posted a $20.8 million operating loss for Q2 2025 ended June 30, up 102% y/y from $9.6 million, driven by ramped R&D spending on the Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa—clinical costs jumped 357% y/y to $7.2 million while CMC expenses rose 341% to $3.3 million. Net loss widened to $20.8 million or $1.92 diluted EPS, versus $98.5 million net income or $(14.07) diluted EPS last year, the latter skewed by a one-time $112 million warrant liability gain now absent after full exercise. Cash burn quickened with $20.8 million used in operations, leaving $113.3 million in cash and short-term investments at quarter-end, bolstered by $70.9 million in Treasury buys yet down from $134.5 million year-start. The AlmataBio acquisition closed in March 2024 for $27.2 million in stock and cash, recognizing $27.6 million IPR&D expense. Free cash flow not disclosed in the 10-Q. Clinical trials demand heavy funding.
ABVX
Abivax SA
98.94+4.70
ATXI
Avenue Therapeutics, Inc.
0.72+0.00
ATXS
Astria Therapeutics, Inc.
12.60+0.13
AURX
Nuo Therapeutics, Inc.
2.29+0.00
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
FBRX
Forte Biosciences, Inc.
14.38+0.92
GLTO
Galecto, Inc.
7.47+0.31
SABS
SAB Biotherapeutics, Inc.
3.04+0.02
TRML
Tourmaline Bio, Inc.
47.98+47.98
XLO
Xilio Therapeutics, Inc.
0.81-0.01